This trial is evaluating whether Treatment will improve 8 primary outcomes and 14 secondary outcomes in patients with Memory Loss. Measurement will happen over the course of Change in assessment scores from baseline to 6-months, 12-months, and 18-months.
This trial requires 225 total participants across 2 different treatment groups
This trial involves 2 different treatments. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"Results from a recent paper found that depression, as indicated by poorer sleep quality, greater self-criticism and increased worry was associated with impaired recall performance on verbal and visuospatial episodic memory tasks. It concluded that memory impairment in depression occurs more than just affecting one sub-executive cognitive function. Sleep quality, self-criticism, worry and depression severity were significant factors in regards to recall performance and recall performance was significantly related to memory performance. This emphasizes the importance of screening for memory loss in depressed patients with a depressive episode. Cognitive deficits in depression can be addressed through different treatments, including the use of antidepressants." - Anonymous Online Contributor
"This article presents the history, causes of and treatment of memory problems. It reviews the clinical and research evidence from relevant literature. It discusses treatment options based on current knowledge and professional treatment guidelines.\n" - Anonymous Online Contributor
"The ability to learn new information and keep it remembered over time is reliant on the ability to encode new information and, in the short term, to retain the information already encoded. When the ability to encode and/or retain knowledge is compromised by injury or disease, this cognitive function cannot be restored." - Anonymous Online Contributor
"Memory loss is a common complaint in the primary care setting. The diagnosis of memory loss is a challenging clinical problem for primary care practitioners. In general, the primary care practitioner must be aware that a patient with memory impairment is likely to have a significant underlying medical, psychological, or social issue. Although memory loss is sometimes described as a gradual process, the symptoms may be episodic or sudden in onset. The first criterion for memory loss (or amnesis) is, by definition, a complaint (without proof of objective loss of memory from a comprehensive neurological examination)." - Anonymous Online Contributor
"Memory loss among elderly people is a growing issue. To support and enhance older adults' capacity for physical and mental health in daily activities, memory-enriching strategies need to be developed and implemented with elderly people in the healthcare system." - Anonymous Online Contributor
"A variety of common treatment options are used for the prevention or treatment of cognitive symptoms experienced by individuals with a diagnosis of a primary memory disorder. A large percentage of cases can be remedied through the administration of pharmacological treatments, particularly stimulant medications (cognitive performance enhancing stimulants), and in some cases, a cognitive training and rehabilitation program (e.g., cognitive behavioural therapy (CBT), pharmacotherapy, etc.). The choice of intervention method can also depend on individual patient characteristics. For many individuals with a primary memory disorder, no treatment for their memory difficulties is available." - Anonymous Online Contributor
"There was no statistically significant difference in mean difference scores in recall from the three methods. The number of items recalled did not appear to be influenced by the technique used, but the number who forgot an item did appear to be influenced by the technique used." - Anonymous Online Contributor
"The authors suggest that memory treatment improves patient outcomes by helping patients and their families accept their treatment, deal with painful cancer treatments and adverse events, and live better lives after treatment is complete. A more complete and longer follow-up will be needed to determine sustained clinical benefit." - Anonymous Online Contributor
"There is no clear evidence that the addition of a proinflammatory immune stimulant to antirentroviral therapy improves CD4+ T-cell recovery despite similar viral load suppression and improvement in memory T-cell reconstitution." - Anonymous Online Contributor
"It is usually around 60-65 years of age. A person may develop symptoms as early as ages 41-47; however, if symptoms are present and the person is not wearing any corrective lenses, the first visit for memory loss is usually due to hearing impairment rather than Alzheimer's.\n" - Anonymous Online Contributor
"Nearly all patients used the same combination of treatment as they did when initially diagnosed with dementia. Almost all patients who were diagnosed with dementia at the time they were receiving care at a residential memory care facility also received that care later. This suggests that clinicians often do not specify the treatment they use in patients they treated in the earlier period." - Anonymous Online Contributor
"Most people can safely start on HD for 3-6 months. Most people who start on HD gain weight, and gain weight more slowly than those who continue to take DMZ. There are rare adverse effects, but they are uncommon and generally disappear after 4 months-5 years." - Anonymous Online Contributor